Synthesis and Receptor Binding Studies of α5 GABAAR Selective Novel Imidazodiazepines Targeted for Psychiatric and Cognitive Disorders
Molecules · 2023
DOI: 10.3390/molecules28124771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Dishary Sharmin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin Milwaukee, Milwaukee, WI 53201, USA. Hauptthemen laut MEDLINE: Receptors, GABA-A, Cognitive Dysfunction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, NIDA NIH HHS, National Institutes of Health (USA).
Abstract (Originalsprache)
GABA mediates inhibitory actions through various GABAA receptor subtypes, including 19 subunits in human GABAAR. Dysregulation of GABAergic neurotransmission is associated with several psychiatric disorders, including depression, anxiety, and schizophrenia. Selective targeting of α2/3 GABAARs can treat mood and anxiety, while α5 GABAA-Rs can treat anxiety, depression, and cognitive performance. GL-II-73 and MP-III-022, α5-positive allosteric modulators have shown promising results in animal models of chronic stress, aging, and cognitive disorders, including MDD, schizophrenia, autism, and Alzheimer’s disease. Described in this article is how small changes in the structure of imidazodiazepine substituents can greatly impact the subtype selectivity of benzodiazepine GABAAR. To investigate alternate and potentially more effective therapeutic compounds, modifications were made to the structure of imidazodiazepine 1 to synthesize different amide analogs. The novel ligands were screened at the NIMH PDSP against a panel of 47 receptors, ion channels, including hERG, and transporters to identify on- and off-target interactions. Any ligands with significant inhibition in primary binding were subjected to secondary binding assays to determine their Ki values. The newly synthesized imidazodiazepines were found to have variable affinities for the benzodiazepine site and negligible or no binding to any off-target profile receptors that could cause other physiological problems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin Milwaukee, Milwaukee, WI 53201, USA.
- Campbell Family Mental Health Research Institute of CAMH, Toronto, ON M5S 2S1, Canada.
- Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5T 1R8, Canada.
- Laboratory of Antiepileptic Drug Discovery, Ascension, St. Vincent, Indianapolis, IN 46260, USA.
ORCID-Profile: Thomas D Prevot, James M Cook
Förderung
- NIAAA NIH HHS
- NIDA NIH HHS
- National Institutes of Health (USA)
Zitieren
APA
Sharmin, D., Mian, M. Y., Marcotte, M., Prevot, T. D., Sibille, E., Witkin, J. M., & Cook, J. M. (2023). Synthesis and Receptor Binding Studies of α5 GABAAR Selective Novel Imidazodiazepines Targeted for Psychiatric and Cognitive Disorders. Molecules. https://doi.org/10.3390/molecules28124771
Vancouver
Sharmin D, Mian MY, Marcotte M, Prevot TD, Sibille E, Witkin JM, et al. Synthesis and Receptor Binding Studies of α5 GABAAR Selective Novel Imidazodiazepines Targeted for Psychiatric and Cognitive Disorders. Molecules. 2023. doi:10.3390/molecules28124771
BibTeX
@article{Sharmin2023,
author = {Sharmin, Dishary and Mian, Md Yeunus and Marcotte, Michael and Prevot, Thomas D and Sibille, Etienne and Witkin, Jeffrey M and Cook, James M},
title = {Synthesis and Receptor Binding Studies of α5 GABAAR Selective Novel Imidazodiazepines Targeted for Psychiatric and Cognitive Disorders},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28124771}
}
EUVIMED